Drug Trial Radar · NCT03970447
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,250
Planned (sponsor's estimate)
Start
Jul 30, 2019
Primary completion
Jun 2028
Study completion Jun 2030
Sponsor
- Lead sponsor
- Global Coalition for Adaptive ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bayer; Kazia Therapeutics Limited; Kintara Therapeutics, Inc.; Biohaven Pharmaceuticals, Inc.; Vigeo Therapeutics, Inc.; Polaris Group; AstraZeneca; Knoa Pharma
- First posted
- May 31, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).
Conditions
- Glioblastoma
Interventions
TemozolomideDrug
Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
LomustineDrug
Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
RegorafenibDrug
Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
RadiationRadiation
60 Gy
PaxalisibDrug
Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
VAL-083Drug
Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
VT1021Drug
Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration.
TroriluzoleDrug
Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
ADI-PEG 20Biological
Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
AZD1390Drug
Standard Regimen Newly Diagnosed: Given once daily on days of radiation and once daily for 14 consecutive days after completion of radiation.
TinostamustineDrug
Dosage form: Reconstituted powder for intravenous administration Strength: 2mg/mL Standard Regimen: Dose as confirmed through the dose finding phase, on Day 1 of 21-day cycle for up to 12 cycles in the maintenance phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From date of randomization until the date of death from any cause, or until 12 months following last patient randomization (approximately 2 years), whichever comes first.
Locations
63 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of California, San Diego
La Jolla, California · Recruiting
Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California · Active not recruiting
University of California, Los Angeles
Los Angeles, California · Active not recruiting
St. Joseph Hospital
Orange, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Stanford Cancer Center
Stanford, California · Completed
University of Colorado Denver
Aurora, Colorado · Recruiting
Yale Cancer Center / Smilow Cancer Hospital*
New Haven, Connecticut · Recruiting
Mayo Clinic Cancer Center
Jacksonville, Florida · Completed
Sylvester Comprehensive Cancer Center*
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Piedmont Atlanta Hospital
Atlanta, Georgia · Active not recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Active not recruiting
LSU Health Sciences Center - New Orleans
New Orleans, Louisiana · Completed
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Health System
Detroit, Michigan · Completed
Allina Health Systems/Abbott Northwestern Hospital
Minneapolis, Minnesota · Recruiting
Mayo Clinic Cancer Center - Rochester
Rochester, Minnesota · Completed
University of Mississippi Medical Center
Jackson, Mississippi · Completed
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri · Completed
Perlmutter Cancer Center, NYU Langone Health
New York, New York · Active not recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Active not recruiting
Columbia University Medical Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center*
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Active not recruiting
Comprehensive Cancer Center of Wake Forest*
Winston-Salem, North Carolina · Recruiting
University Hospitals Cleveland Medical Center*
Cleveland, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Ohio State University Cancer Center
Columbus, Ohio · Active not recruiting
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania · Active not recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania · Completed
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania · Active not recruiting
Medical University of South Carolina - Hollings Cancer Center
Charleston, South Carolina · Recruiting
Texas Oncology - Austin
Austin, Texas · Active not recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Active not recruiting
University of Texas - MD Anderson Cancer Center
Houston, Texas · Active not recruiting
University of Utah - Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
University of Virginia Health
Charlottesville, Virginia · Recruiting
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.